Recent 8-K filings for ORGO

• May 7, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01 ◈ Earnings Releases

  Organogenesis Q1 revenue $36.3M (-58% YoY); net loss $53.2M; FY guidance lowered

  Net revenue $36.3M, down 58% YoY from $86.7M; Advanced Wound Care down 63% to $29.5M.

• February 26, 2026, 6:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline

  Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).

• February 23, 2026, 6:59 PM ET leadership materiality 0.30 neutral item 5.02

  Organogenesis appoints Patrick McGuire as CAO; Francisco remains CFO

  Patrick McGuire, 40, appointed Chief Accounting Officer and principal accounting officer effective Feb 18, 2026; was VP Corporate Controller since Sep 2023.

• December 29, 2025, 6:59 PM ET other material materiality 0.35 neutral item 1.01item 9.01 ◈ Material Agreements

  Organogenesis extends Canton lease terms through 2032 with related-party landlords; rent escalates 3% annually

  Extended leases at 65 Dan Road and 150 Dan Road from Dec 31, 2027 to Dec 31, 2032, with an option to extend to Dec 31, 2034.

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Organogenesis posts record Q3 revenue of $150.5M, raises FY2025 guidance

  Net product revenue $150.5M (+31% YoY); Advanced Wound Care $141.5M (+31%), Surgical & Sports Med $9.0M (+25%).

• September 25, 2025, 7:59 PM ET other material materiality 0.80 negative item 7.01item 8.01item 9.01

  Organogenesis second Phase 3 ReNu knee OA trial misses primary endpoint; pre-BLA meeting planned

  Second Phase 3 (n=594) did not meet primary endpoint: WOMAC pain reduction difference -0.5 favoring ReNu (p=0.0393 vs target p=0.023).

• August 7, 2025, 7:59 PM ET earnings materiality 0.85 negative item 1.01item 2.02item 9.01

  Organogenesis Q2 revenue down 23% to $100.8M; amends credit agreement, waives covenant test

  Net product revenue $100.8M (down 23% YoY); Advanced Wound Care fell 25%, Surgical & Sports Med up 16%.

• June 24, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.02item 5.07

  Organogenesis stockholders approve Series A conversion issuance and director elections at 2025 annual meeting

  Stockholders approved issuance of >20% of Class A common stock upon conversion of Series A Preferred at less than Nasdaq minimum price.

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Organogenesis Q1 revenue down 21% to $86.7M; net loss widens to $18.8M; FY guidance reaffirmed

  Net revenue $86.7M, down 21% YoY; Advanced Wound Care fell 23% to $79.9M; Surgical & Sports Medicine up 11% to $6.8M.

• March 27, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  Organogenesis posts investor presentation with no disclosed material changes; details unavailable

  Company posted investor presentation to its website on March 27, 2025.

• February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Organogenesis Q4 revenue up 27% to $126.7M; net income $7.7M vs loss year ago; guides FY25 rev $480-535M

  Q4 net revenue $126.7M (+27%); Advanced Wound Care $118.6M (+27%), Surgical/Sports $8.1M (+24%).

• December 2, 2024, 6:59 PM ET other material materiality 0.35 neutral item 1.01item 9.01

  Organogenesis repurchases 500K shares from director trust at $4.057/sh for $2M total

  Repurchase of 500,000 shares from GN 2016 Family Trust (related to director Glenn Nussdorf) at $4.057/share, total $2.03M.

• November 22, 2024, 6:59 PM ET other material materiality 0.55 positive item 1.01item 8.01item 9.01

  Organogenesis signs 16.5-year lease for 122,000 sq ft RI biomanufacturing facility, base rent $43/sq ft from 2026

  Leased 122,000 sq ft at 100 Technology Way, Smithfield, RI for biomanufacturing expansion.

• November 13, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01item 5.03item 2.04item 3.02item 3.03item 5.02item 8.01item 9.01 ◈ executive_change

  Organogenesis raises $130M convertible preferred, repurchases 7.4M shares, appoints Avista director

  Sold 130,000 shares of Series A Convertible Preferred Stock at $1,000/share for gross proceeds of $130M.

• November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Organogenesis Q3 revenue up 6% to $115.2M, net income $12.3M vs $3.2M; updates FY guidance

  Net revenue $115.2M (+6% YoY); Advanced Wound Care $108.0M (+7%).

• August 8, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Organogenesis Q2 revenue up 11% but net loss $17M on $22.8M impairment and write-downs

  Net revenue $130.2M (+11% YoY); Advanced Wound Care $123.2M (+12%), Surgical & Sports Med $7.0M (-3%).

• June 21, 2024, 7:59 PM ET other materiality 0.30 neutral item 5.02item 5.07item 9.01

  Stockholders approve 15.9M share increase to 2018 Equity Incentive Plan

  All 11 director nominees elected; votes ranged from 41.5M to 68.4M for, with broker non-votes of 39.3M.

• May 9, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M

  Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.

• April 3, 2024, 7:59 PM ET litigation materiality 0.55 positive item 8.01item 9.01

  Court dismisses securities fraud lawsuit against Organogenesis, CEO and CFO with prejudice

  U.S. District Court for Eastern District of New York granted motion to dismiss on March 29, 2024.

• February 29, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M

  Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

7 positive 7 negative 6 neutral

source · ORGO on sec.gov